# Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

> **NCT05910177** · PHASE2 · RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Carcinoma
- Cervix Carcinoma

## Interventions

- **DRUG:** Karelizumab combined with etoposide and cisplatin

## Key facts

- **NCT ID:** NCT05910177
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-28
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05910177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05910177, "Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05910177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*